EA024392B1 - Феноксиэтилпиперидиновые соединения - Google Patents

Феноксиэтилпиперидиновые соединения Download PDF

Info

Publication number
EA024392B1
EA024392B1 EA201492255A EA201492255A EA024392B1 EA 024392 B1 EA024392 B1 EA 024392B1 EA 201492255 A EA201492255 A EA 201492255A EA 201492255 A EA201492255 A EA 201492255A EA 024392 B1 EA024392 B1 EA 024392B1
Authority
EA
Eurasian Patent Office
Prior art keywords
mmol
methyl
ethyl
formula
mixture
Prior art date
Application number
EA201492255A
Other languages
English (en)
Russian (ru)
Other versions
EA201492255A1 (ru
Inventor
Мэтью Аллен Шиффлер
Джереми Шуленбург Йорк
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201492255A1 publication Critical patent/EA201492255A1/ru
Publication of EA024392B1 publication Critical patent/EA024392B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201492255A 2012-06-29 2013-06-20 Феноксиэтилпиперидиновые соединения EA024392B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (2)

Publication Number Publication Date
EA201492255A1 EA201492255A1 (ru) 2015-03-31
EA024392B1 true EA024392B1 (ru) 2016-09-30

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492255A EA024392B1 (ru) 2012-06-29 2013-06-20 Феноксиэтилпиперидиновые соединения

Country Status (43)

Country Link
US (2) US8962659B2 (ja)
EP (1) EP2867207B1 (ja)
JP (1) JP6127136B2 (ja)
KR (1) KR101653476B1 (ja)
CN (1) CN104411684B (ja)
AP (1) AP2014008164A0 (ja)
AR (1) AR091429A1 (ja)
AU (1) AU2013280875B2 (ja)
BR (1) BR112014031616B1 (ja)
CA (1) CA2875569C (ja)
CL (1) CL2014003535A1 (ja)
CO (1) CO7151507A2 (ja)
CR (1) CR20140553A (ja)
CY (1) CY1119425T1 (ja)
DK (1) DK2867207T3 (ja)
DO (1) DOP2014000287A (ja)
EA (1) EA024392B1 (ja)
EC (1) ECSP14033267A (ja)
ES (1) ES2644812T3 (ja)
GT (1) GT201400288A (ja)
HK (1) HK1203937A1 (ja)
HR (1) HRP20171515T1 (ja)
HU (1) HUE034425T2 (ja)
IL (1) IL236219A (ja)
JO (1) JO3296B1 (ja)
LT (1) LT2867207T (ja)
MA (1) MA37686B1 (ja)
ME (1) ME02840B (ja)
MX (1) MX345324B (ja)
MY (1) MY173878A (ja)
NZ (1) NZ701933A (ja)
PE (1) PE20150182A1 (ja)
PH (1) PH12015500009B1 (ja)
PL (1) PL2867207T3 (ja)
PT (1) PT2867207T (ja)
RS (1) RS56452B1 (ja)
SG (1) SG11201408641UA (ja)
SI (1) SI2867207T1 (ja)
TN (1) TN2014000501A1 (ja)
TW (1) TWI599561B (ja)
UA (1) UA114325C2 (ja)
WO (1) WO2014004229A1 (ja)
ZA (1) ZA201408632B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI636046B (zh) * 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
WO2015094902A1 (en) * 2013-12-17 2015-06-25 Eli Lilly And Company Phenoxyethyl cyclic amine derivatives and their activity as ep4 receptor modulators
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CA3063632A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
EA201992677A1 (ru) 2017-05-18 2020-04-23 Идорсия Фармасьютиклз Лтд Пиримидиновые производные в качестве модуляторов pge2 рецепторов
CA3063637A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
LT3625222T (lt) 2017-05-18 2021-11-10 Idorsia Pharmaceuticals Ltd Fenilo dariniai, kaip pge2 receptoriaus moduliatoriai
AU2020212111A1 (en) * 2019-01-22 2021-08-05 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP4245301A1 (en) 2020-11-13 2023-09-20 ONO Pharmaceutical Co., Ltd. Cancer treatment by combined use of ep4 antagonist and immune checkpoint inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105732A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds
WO2013004290A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor antagonists
WO2013004291A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor agonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
EP1487437B1 (en) * 2002-03-18 2006-08-16 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of diseases
WO2004063158A1 (en) * 2003-01-10 2004-07-29 F.Hoffmann-La Roche Ag 2-piperidone derivatives as prostaglandin agonists
MXPA06002551A (es) * 2003-09-03 2006-06-20 Pfizer Compuestos de aril o heteroaril amida.
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ES2392192T3 (es) 2006-04-24 2012-12-05 Merck Canada Inc. Derivados de indol amida como antagonistas del receptor EP4
CA2654811A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
US8598355B2 (en) * 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
CA2733247C (en) 2008-08-14 2018-04-03 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
BR112012020236A2 (pt) 2010-02-22 2016-05-17 Raqualia Pharma Inc uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero
WO2012039972A1 (en) * 2010-09-21 2012-03-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition
AR091429A1 (es) * 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005105732A1 (en) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
US20050250818A1 (en) * 2004-05-04 2005-11-10 Pfizer Inc Ortho substituted aryl or heteroaryl amide compounds
WO2013004290A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor antagonists
WO2013004291A1 (en) * 2011-07-04 2013-01-10 Rottapharm S.P.A. Cyclic amine derivatives as ep4 receptor agonists

Also Published As

Publication number Publication date
US8962659B2 (en) 2015-02-24
CA2875569A1 (en) 2014-01-03
CL2014003535A1 (es) 2015-05-08
GT201400288A (es) 2015-08-27
DOP2014000287A (es) 2015-01-31
US20140005226A1 (en) 2014-01-02
CR20140553A (es) 2015-02-04
SG11201408641UA (en) 2015-01-29
SI2867207T1 (sl) 2017-10-30
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
KR101653476B1 (ko) 2016-09-01
UA114325C2 (uk) 2017-05-25
MY173878A (en) 2020-02-26
TN2014000501A1 (en) 2016-03-30
HK1203937A1 (en) 2015-11-06
TWI599561B (zh) 2017-09-21
HUE034425T2 (en) 2018-02-28
PL2867207T3 (pl) 2018-01-31
BR112014031616B1 (pt) 2022-06-21
PT2867207T (pt) 2017-11-01
LT2867207T (lt) 2017-10-10
HRP20171515T1 (hr) 2017-11-17
ME02840B (me) 2018-01-20
CO7151507A2 (es) 2014-12-29
IL236219A0 (en) 2015-02-01
ES2644812T3 (es) 2017-11-30
AP2014008164A0 (en) 2014-12-31
MA37686A1 (fr) 2016-09-30
JP6127136B2 (ja) 2017-05-10
AU2013280875A1 (en) 2014-12-04
PH12015500009A1 (en) 2015-03-02
CA2875569C (en) 2016-04-19
JP2015522018A (ja) 2015-08-03
WO2014004229A1 (en) 2014-01-03
JO3296B1 (ar) 2018-09-16
TW201412717A (zh) 2014-04-01
ZA201408632B (en) 2017-06-28
IL236219A (en) 2017-12-31
DK2867207T3 (en) 2017-09-11
CY1119425T1 (el) 2018-03-07
PH12015500009B1 (en) 2015-03-02
PE20150182A1 (es) 2015-02-13
CN104411684B (zh) 2016-08-24
EP2867207A1 (en) 2015-05-06
EP2867207B1 (en) 2017-08-09
US9402838B2 (en) 2016-08-02
EA201492255A1 (ru) 2015-03-31
MA37686B1 (fr) 2017-04-28
KR20150013893A (ko) 2015-02-05
AR091429A1 (es) 2015-02-04
MX2014015953A (es) 2015-07-17
US20150126555A1 (en) 2015-05-07
AU2013280875B2 (en) 2015-09-24
BR112014031616A2 (pt) 2017-06-27
MX345324B (es) 2017-01-25
NZ701933A (en) 2017-01-27
RS56452B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
EA024392B1 (ru) Феноксиэтилпиперидиновые соединения
JP6212644B2 (ja) フェノキシエチル環状アミン誘導体およびep4受容体モジュレーターとしてのその活性
AU2013280779B2 (en) Dimethyl-benzoic acid compounds
JP6148400B2 (ja) フェノキシエチルジヒドロ−1h−イソキノリン化合物
US9000043B2 (en) Phenoxyethoxy compounds
WO2004069788A1 (ja) カルボン酸化合物
JP2007186422A (ja) アリールスルフィド誘導体
AU2014265762B2 (en) Phenoxyethyl dihydro-1H-isoquinoline compounds

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM